These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 15878055)

  • 41. Intravitreal triamcinolone acetonide injection for the treatment of posterior uveitis.
    Ozkiris A
    Ocul Immunol Inflamm; 2006 Aug; 14(4):233-8. PubMed ID: 16911985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intraoperative use of intravitreal triamcinolone in uveitic eyes having cataract surgery: pilot study.
    Okhravi N; Morris A; Kok HS; Menezo V; Dowler JG; Hykin PG; Lightman S
    J Cataract Refract Surg; 2007 Jul; 33(7):1278-83. PubMed ID: 17586387
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
    Westhovens R; Houssiau F; Joly J; Everitt DE; Zhu Y; Sisco D; Van Hartingsveldt B; Mascelli MA; Graham MA; Durez P; Bouman-Thio E
    J Rheumatol; 2006 May; 33(5):847-53. PubMed ID: 16583466
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis.
    Plskova J; Greiner K; Forrester JV
    Am J Ophthalmol; 2007 Jul; 144(1):55-61. PubMed ID: 17601428
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.
    Rosenfeld PJ; Schwartz SD; Blumenkranz MS; Miller JW; Haller JA; Reimann JD; Greene WL; Shams N
    Ophthalmology; 2005 Jun; 112(6):1048-53. PubMed ID: 15885778
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis.
    Murphy CC; Greiner K; Plskova J; Frost NA; Forrester JV; Dick AD
    Br J Ophthalmol; 2007 Feb; 91(2):154-6. PubMed ID: 16973657
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcome of Treating Pediatric Uveitis With Dexamethasone Implants.
    Tomkins-Netzer O; Talat L; Seguin-Greenstein S; Bar A; Lightman S
    Am J Ophthalmol; 2016 Jan; 161():110-5.e1-2. PubMed ID: 26478217
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis.
    Krueger JG; Walters IB; Miyazawa M; Gilleaudeau P; Hakimi J; Light S; Sherr A; Gottlieb AB
    J Am Acad Dermatol; 2000 Sep; 43(3):448-58. PubMed ID: 10954656
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.
    Suhler EB; Thorne JE; Mittal M; Betts KA; Tari S; Camez A; Bao Y; Joshi A
    Ophthalmology; 2017 Dec; 124(12):1799-1807. PubMed ID: 28689898
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis.
    Lowder C; Belfort R; Lightman S; Foster CS; Robinson MR; Schiffman RM; Li XY; Cui H; Whitcup SM;
    Arch Ophthalmol; 2011 May; 129(5):545-53. PubMed ID: 21220619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program.
    Merrill PT; Clark WL; Banker AS; Fardeau C; Franco P; LeHoang P; Ohno S; Rathinam SR; Ali Y; Mudumba S; Shams N; Nguyen QD;
    Ophthalmology; 2020 Oct; 127(10):1405-1415. PubMed ID: 32564920
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis.
    Jaffe GJ
    Am J Ophthalmol; 2008 Apr; 145(4):667-675. PubMed ID: 18226800
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ranibizumab for refractory uveitis-related macular edema.
    Acharya NR; Hong KC; Lee SM
    Am J Ophthalmol; 2009 Aug; 148(2):303-309.e2. PubMed ID: 19427988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mycophenolate sodium for immunosuppressive treatment in uveitis.
    Deuter CM; Doycheva D; Stuebiger N; Zierhut M
    Ocul Immunol Inflamm; 2009; 17(6):415-9. PubMed ID: 20001262
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.
    Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group
    Ophthalmology; 2015 Oct; 122(10):1976-86. PubMed ID: 26298718
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early treatment of severe cystoid macular edema in central retinal vein occlusion with posterior sub-tenon triamcinolone acetonide.
    Lin JM; Chiu YT; Hung PT; Tsai YY
    Retina; 2007 Feb; 27(2):180-9. PubMed ID: 17290200
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vitreous surgery in the management of chronic endogenous posterior uveitis.
    Scott RA; Haynes RJ; Orr GM; Cooling RJ; Pavésio CE; Charteris DG
    Eye (Lond); 2003 Mar; 17(2):221-7. PubMed ID: 12640410
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis.
    Van Assche G; Dalle I; Noman M; Aerden I; Swijsen C; Asnong K; Maes B; Ceuppens J; Geboes K; Rutgeerts P
    Am J Gastroenterol; 2003 Feb; 98(2):369-76. PubMed ID: 12591057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.